-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Finch Therapeutics to Participate in Upcoming June Investor Conferences
Finch Therapeutics to Participate in Upcoming June Investor Conferences
SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in fireside chats at the following investor conferences:
- Jefferies Healthcare Conference on Friday, June 10, 2022 at 8:00 am ET in New York, NY
- JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 2:00 pm ET in New York, NY
Live webcasts of the fireside chats will be available under the "Investors & News" section of the Finch website and will be archived for approximately 30 days following each event.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch's lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is also developing FIN-211 for children with autism spectrum disorder and significant gastrointestinal symptoms. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease. Finch routinely posts information that may be important to its investors on its website at . Finch encourages investors to consult the "Investors & News" section of its website regularly.
Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com
SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in fireside chats at the following investor conferences:
环球通讯社，马萨诸塞州萨默维尔，2022年6月2日--芬奇治疗集团(以下简称芬奇或芬奇治疗公司)(纳斯达克代码：FNCH)，一家临床阶段微生物组治疗公司，利用其人类第一的发现开发一种新型口服生物药物的®平台今天宣布，首席执行官马克·史密斯博士将参加以下投资者会议的炉边聊天：
- Jefferies Healthcare Conference on Friday, June 10, 2022 at 8:00 am ET in New York, NY
- JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 2:00 pm ET in New York, NY
- 杰富瑞医疗会议将于2022年6月10日星期五美国东部时间上午8：00在纽约举行
- JMP证券生命科学会议将于2022年6月15日星期三，美国东部时间下午2：00在纽约举行
Live webcasts of the fireside chats will be available under the "Investors & News" section of the Finch website and will be archived for approximately 30 days following each event.
炉边聊天的网络直播将在Finch网站的“投资者和新闻”栏目下进行，并将在每次活动后存档约30天。
About Finch Therapeutics
芬奇治疗公司简介
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch's lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is also developing FIN-211 for children with autism spectrum disorder and significant gastrointestinal symptoms. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease. Finch routinely posts information that may be important to its investors on its website at . Finch encourages investors to consult the "Investors & News" section of its website regularly.
芬奇治疗公司是一家临床阶段的微生物组治疗公司，利用其人类第一的发现®平台开发一类新型口服生物药物。凭借开发完整和有针对性的微生物组疗法的能力，Finch正在推进一系列丰富的候选药物，旨在解决广泛的未得到满足的医疗需求。芬奇的主要候选药物CP101正处于预防复发的晚期临床开发阶段艰难梭菌并已获得美国食品和药物管理局的突破性治疗和快速通道称号。芬奇还在为患有自闭症谱系障碍和严重胃肠道症状的儿童开发FIN-211。芬奇与武田建立了合作伙伴关系，专注于开发治疗炎症性肠病的靶向微生物组疗法。Finch经常在其网站上发布对投资者可能重要的信息。芬奇鼓励投资者定期咨询其网站上的“投资者与新闻”栏目。
Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.
人类第一的发现®是芬奇治疗集团公司的注册商标。
Investor Contact:
投资者联系方式：
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
史蒂芬·贾斯珀
吉尔马丁集团
(858) 525-2047
邮箱：stephen@gilmartinir.com
Media Contact:
媒体联系人：
Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com
珍娜·厄本
贝瑞与公司公关
(212) 253-8881
邮箱：jUrban@berrypr.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧